Introducing Valuation Models! 
Key Stats for Verve Stock
- Yesterday’s Price Change: 81%
- Current Share Price: $11.38
- 52-Week High: $11.41
- VERV Stock Price Target: $24.33
What Happened?
Verve Therapeutics (VERV) stock rocketed 81% after pharmaceutical giant Eli Lilly announced it would acquire the gene-editing startup for up to $1.3 billion.
Under the deal terms, Lilly will pay $10.50 per share in cash at closing (approximately $1.0 billion), plus offer shareholders a contingent value right (CVR) worth up to an additional $3.00 per share.
The CVR payment would be triggered if Verve successfully doses the first patient with its lead gene-editing medicine VERVE-102 for atherosclerotic cardiovascular disease (ASCVD) in a U.S. Phase 3 clinical trial within 10 years of the deal’s closing.
The $10.50 per share cash consideration represents a massive 113% premium to Verve’s 30-day volume-weighted average trading price, which ended on Monday, the last trading day before the announcement.
VERVE-102 represents a potential breakthrough in cardiovascular treatment. It is a gene editing medicine targeting PCSK9 that could provide lifelong cholesterol reduction with a single dose.
The drug is currently in Phase 1b trials and has received Fast Track designation from the FDA, highlighting its potential to address significant unmet medical needs.
See Verve’s full analyst estimates, earnings results, and earnings transcript (It’s free) >>>
What the Market Is Telling Us
The dramatic surge in Verve’s stock price reflects investor enthusiasm for the immediate financial windfall and validation of the company’s gene editing approach.
The acquisition premium demonstrates Lilly’s confidence in Verve’s technology platform and its potential to transform cardiovascular care from chronic treatment to a “one-and-done” solution.
For Lilly, the deal represents a strategic bet on next-generation gene editing therapies that could revolutionize treatment paradigms.
The healthcare giant views VERVE-102 as potentially the first in vivo gene editing therapy for broad patient populations, addressing conditions such as heterozygous familial hypercholesterolemia, which affects approximately 1 in 250 people globally.
Want to Invest Like Warren Buffett, Joel Greenblatt, or Peter Lynch?
TIKR just published a special report breaking down 5 powerful stock screeners inspired by the exact strategies used by the world’s greatest investors.
In this report, you’ll discover:
- A Buffett-style screener for finding wide-moat compounders at fair prices
- Joel Greenblatt’s formula for high-return, low-risk stocks
- A Peter Lynch-inspired tool to surface fast-growing small caps before Wall Street catches on
Each screener is fully customizable on TIKR, so you can apply legendary investing strategies instantly. Whether you’re looking for long-term compounders or overlooked value plays, these screeners will save you hours and sharpen your edge.
This is your shortcut to proven investing frameworks, backed by real performance data.
Click here to sign up for TIKR and get this full report now, completely free.
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
